



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

April 29, 2022

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2022.

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited


Rajesh Shirambekar
Head – Legal & Company Secretary



Encl.: as above



Q4 FY22 Revenue from operations grew by 12% and PBT grew by 22% Y-o-Y
Full year FY22 Revenue from operations grew by 13% and PBT grew by 37% with EBITDA margin expanding from 18.2% to 20.3% Y-o-Y

Mumbai, 29 April, 2022: RPG Life Sciences Limited has announced its financial results for the quarter and year ended March 31, 2022.

	Y-o-Y Revenue from operations	Y-o-Y PBT
Q4 FY22 Highlights	Rs 103.80 crores – up from Rs 92.76 crores	Rs 10.93 crores – up from Rs 8.95 crores
Full year FY22 Highlights	Rs 440.16 crores – up from Rs 389.14 crores	Rs 73.17 crores – up from Rs 53.58 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in PBT by 22% Y-o-Y for Q4 FY22. Revenue from operations at Rs 103.80 crores registered a growth of 12% Y-o-Y for Q4 FY22. For full year FY22, the company posted a jump in PBT by 37% Y-o-Y and recorded EBITDA margin expansion from 18.2% to 20.3% Y-o-Y. Revenue from operations at Rs 440.16 crores registered a growth of 13% Y-o-Y for full year FY22.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “I am pleased to share that in Q4 FY22, we continued to deliver a robust performance. Revenue and PBT grew by 12% and 22% respectively Y-o-Y. EBITDA margins’ consistent upward trajectory has continued for the last 4 years, growing from 10.4% (FY19) to 15.9% (FY20) to 18.2% (FY21) to 20.3% (FY22). The Company continues to remain debt-free with the highest-ever net cashflow generated from operations in full year FY22.

Domestic Formulations business has recorded a robust growth both in value and volumes - significantly and consistently better than the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. We have successfully forayed into a new therapy area - Rheumatology, which is strengthening our Specialty segment. Salesforce productivity continues to register healthy upward momentum. API business has also recorded robust growth. In the International Formulations business, our growth was somewhat subdued due to the political unrest in one of our key markets, Myanmar. However, the rest of international business has reflected strong performance supported by new launches. Our unique digital initiative, RPGServ, is having impressive traction in physician connect and engagement. Going forward, we stay committed to implementing our Transformation Agenda to grow both topline and bottomline across segments.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Sumeet Chatterjee, +91 9820340650 | sumeet@rpg.in

